Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4⁺ T Cells of Patients with Relapsing-Remitting Multiple Sclerosis

Figure 1

miR-17 differential expression in CD4⁺ T cells of HV and RRMS patients. Transcriptional expression of miR-17 was analyzed with real-time RT-PCR in CD4⁺ T cells from (a) HVs and untreated and natalizumab treated patients (𝑛=14) (bars represent median with interquartile range); (b) two patients on natalizumab therapy who experienced relapse (before, on, and after relapse time points). Relative expression levels are depicted. One-way ANOVA with Tukey’s multiple comparison test was applied.^∗∗∗𝑃<0.001;^∗∗𝑃<0.01.

(a)

(b)